PE20120766A1 - Derivados de quinoxalina como inhibidores de tumores - Google Patents
Derivados de quinoxalina como inhibidores de tumoresInfo
- Publication number
- PE20120766A1 PE20120766A1 PE2011001740A PE2011001740A PE20120766A1 PE 20120766 A1 PE20120766 A1 PE 20120766A1 PE 2011001740 A PE2011001740 A PE 2011001740A PE 2011001740 A PE2011001740 A PE 2011001740A PE 20120766 A1 PE20120766 A1 PE 20120766A1
- Authority
- PE
- Peru
- Prior art keywords
- substituted
- alkyl
- quinoxalin
- urea
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
REFERIDA A UN COMPUESTO DE FORMULA I, DONDE X ES O,S; R1 ES H, ALQUILO C1-C12 SUSTITUIDO O NO, CIANO, HALOGENO; R2 Y R3 SON CADA UNO H, ALQUILO C1-12 SUSTITUIDO O NO; R4 ES H, CICLOALQUILO SUSTITUIDO O NO, HETEROCICLILO SUSTITUIDO O NO; ALQUILARILO SUSTITUIDO O NO, ENTRE OTROS; R5, R6, R7 Y R8 SON CADA UNO H, ALQUILO C1-C12 SUSTITUIDO O NO, ARILO SUSTITUIDO O NO, HETEROARILO SUSTITUIDO O NO, HALOGENO, AMINO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 1-CICLOPENTIL-3-[7-(4-HIDROXI-3-METOXIFENIL)QUINOXALIN-2-IL]UREA; 1-[7-(3,4-DIMETOXIFENIL)QUINOXALIN-2-IL]-3-[1-(2,2,2-TRIFLUOROACETIL)PIPERIDIN-4-IL]UREA; ENTRE OTROS. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE ADEMAS BLEOMICINA, CARBOPLATINO, EPIRUBICINA, IRINOTECAN, VINCRISTINA, ENTRE OTROS, SIENDO UTIL EN EL TRATAMIENTO DE CARCINOMAS METASTASICOS
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16595309P | 2009-04-02 | 2009-04-02 | |
EP09157141A EP2241557A1 (de) | 2009-04-02 | 2009-04-02 | Chinoxalin-Derivate und deren Anwendung zur Behandlung gutartiger und bösartiger Tumorerkrankungen |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20120766A1 true PE20120766A1 (es) | 2012-07-19 |
Family
ID=40886691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2011001740A PE20120766A1 (es) | 2009-04-02 | 2010-03-25 | Derivados de quinoxalina como inhibidores de tumores |
Country Status (20)
Country | Link |
---|---|
US (1) | US8394801B2 (es) |
EP (2) | EP2241557A1 (es) |
JP (1) | JP5583201B2 (es) |
KR (1) | KR20110136888A (es) |
CN (1) | CN102378758A (es) |
AR (1) | AR075935A1 (es) |
AU (1) | AU2010233983A1 (es) |
BR (1) | BRPI1010306A2 (es) |
CA (1) | CA2757138A1 (es) |
CO (1) | CO6501171A2 (es) |
EC (1) | ECSP11011363A (es) |
IL (1) | IL215025A0 (es) |
MX (1) | MX2011010329A (es) |
NZ (1) | NZ595064A (es) |
PE (1) | PE20120766A1 (es) |
RU (1) | RU2532914C2 (es) |
SG (1) | SG175014A1 (es) |
TW (1) | TWI464150B (es) |
UA (1) | UA105211C2 (es) |
WO (1) | WO2010115719A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102464675A (zh) * | 2010-11-12 | 2012-05-23 | 上海医药工业研究院 | 具有抗肿瘤活性的金络合物及其可药用衍生物 |
AU2012289254A1 (en) | 2011-07-26 | 2014-03-13 | Grünenthal GmbH | Substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands |
KR20180030913A (ko) * | 2015-07-30 | 2018-03-26 | 브리스톨-마이어스 스큅 컴퍼니 | 아릴 치환된 비시클릭 헤테로아릴 화합물 |
WO2017205536A2 (en) * | 2016-05-24 | 2017-11-30 | Genentech, Inc. | Therapeutic compounds and uses thereof |
CN110698418B (zh) * | 2019-09-11 | 2022-07-01 | 广西师范大学 | 一种3-芳胺基喹喔啉-2-甲酰胺类衍生物及其制备方法和应用 |
CN115463217B (zh) * | 2021-06-11 | 2024-03-12 | 深圳埃格林医药有限公司 | 己酸羟孕酮在增强肿瘤治疗效果中的应用 |
CN114605391B (zh) * | 2022-02-21 | 2024-01-26 | 广州六顺生物科技股份有限公司 | 喹喔啉类衍生物及其制备方法和应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPN842196A0 (en) | 1996-03-05 | 1996-03-28 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
US6159978A (en) | 1997-05-28 | 2000-12-12 | Aventis Pharmaceuticals Product, Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6245760B1 (en) | 1997-05-28 | 2001-06-12 | Aventis Pharmaceuticals Products, Inc | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6180632B1 (en) | 1997-05-28 | 2001-01-30 | Aventis Pharmaceuticals Products Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
IL133007A (en) | 1997-05-28 | 2005-06-19 | Aventis Pharma Inc | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
IL139783A0 (en) | 1998-06-01 | 2002-02-10 | Shionogi & Co | Cyanoiminoquinoxaline derivates |
UA76977C2 (en) * | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
AU2003243318A1 (en) * | 2002-05-29 | 2003-12-19 | Millennium Pharmaceuticals, Inc. | Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer |
US20070254894A1 (en) | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
WO2008015423A1 (en) | 2006-08-01 | 2008-02-07 | Sentinel Oncology Limited | Quinoline and quinoxaline n-oxides as chk-1 inhibitors |
TW200902008A (en) | 2007-05-10 | 2009-01-16 | Smithkline Beecham Corp | Quinoxaline derivatives as PI3 kinase inhibitors |
EP1990342A1 (en) * | 2007-05-10 | 2008-11-12 | AEterna Zentaris GmbH | Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof |
-
2009
- 2009-04-02 EP EP09157141A patent/EP2241557A1/de not_active Withdrawn
-
2010
- 2010-03-25 SG SG2011071610A patent/SG175014A1/en unknown
- 2010-03-25 CA CA2757138A patent/CA2757138A1/en not_active Abandoned
- 2010-03-25 UA UAA201111539A patent/UA105211C2/ru unknown
- 2010-03-25 CN CN201080014936XA patent/CN102378758A/zh active Pending
- 2010-03-25 US US12/731,243 patent/US8394801B2/en not_active Expired - Fee Related
- 2010-03-25 AR ARP100100940A patent/AR075935A1/es unknown
- 2010-03-25 WO PCT/EP2010/053891 patent/WO2010115719A1/en active Application Filing
- 2010-03-25 KR KR1020117026033A patent/KR20110136888A/ko not_active Application Discontinuation
- 2010-03-25 JP JP2012502582A patent/JP5583201B2/ja not_active Expired - Fee Related
- 2010-03-25 EP EP10710051A patent/EP2419411A1/en not_active Withdrawn
- 2010-03-25 TW TW099108919A patent/TWI464150B/zh not_active IP Right Cessation
- 2010-03-25 AU AU2010233983A patent/AU2010233983A1/en not_active Abandoned
- 2010-03-25 NZ NZ595064A patent/NZ595064A/xx unknown
- 2010-03-25 PE PE2011001740A patent/PE20120766A1/es not_active Application Discontinuation
- 2010-03-25 MX MX2011010329A patent/MX2011010329A/es active IP Right Grant
- 2010-03-25 RU RU2011138477/04A patent/RU2532914C2/ru not_active IP Right Cessation
- 2010-03-25 BR BRPI1010306A patent/BRPI1010306A2/pt not_active IP Right Cessation
-
2011
- 2011-09-07 IL IL215025A patent/IL215025A0/en unknown
- 2011-09-30 EC EC2011011363A patent/ECSP11011363A/es unknown
- 2011-09-30 CO CO11128635A patent/CO6501171A2/es active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
IL215025A0 (en) | 2011-11-30 |
RU2011138477A (ru) | 2013-05-10 |
BRPI1010306A2 (pt) | 2017-05-16 |
WO2010115719A1 (en) | 2010-10-14 |
EP2241557A1 (de) | 2010-10-20 |
CN102378758A (zh) | 2012-03-14 |
CO6501171A2 (es) | 2012-08-15 |
CA2757138A1 (en) | 2010-10-14 |
US20100266538A1 (en) | 2010-10-21 |
TW201100391A (en) | 2011-01-01 |
NZ595064A (en) | 2013-10-25 |
TWI464150B (zh) | 2014-12-11 |
SG175014A1 (en) | 2011-11-28 |
ECSP11011363A (es) | 2011-10-31 |
JP5583201B2 (ja) | 2014-09-03 |
US8394801B2 (en) | 2013-03-12 |
KR20110136888A (ko) | 2011-12-21 |
MX2011010329A (es) | 2011-10-17 |
EP2419411A1 (en) | 2012-02-22 |
AU2010233983A1 (en) | 2011-10-06 |
UA105211C2 (ru) | 2014-04-25 |
RU2532914C2 (ru) | 2014-11-20 |
AR075935A1 (es) | 2011-05-04 |
JP2012522741A (ja) | 2012-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20120766A1 (es) | Derivados de quinoxalina como inhibidores de tumores | |
PE20120693A1 (es) | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) | |
PE20130647A1 (es) | Indoles | |
PE20050087A1 (es) | Derivados de 2-oxodihidropiridina n-sustituidos | |
PE20121282A1 (es) | Antagonistas de espiro-oxindol de mdm2 | |
PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
PE20091466A1 (es) | Derivados de 4,5-dihidro-oxazol-2-il-amina | |
PE20090237A1 (es) | Derivados de sulfonamidas como inhibidores de los canales de sodio | |
PE20220597A1 (es) | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos | |
PE20090718A1 (es) | Derivados de espiroindolinona | |
PE20130229A1 (es) | Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cancer | |
PE20190175A1 (es) | Compuestos de pirrolotriazina como inhibidores de tam | |
PE20090709A1 (es) | Compuestos heterociclico de 5 miembros | |
PE20142185A1 (es) | Pirrolidina-2-carboxamidas sustituidas | |
PE20090610A1 (es) | Derivados de pirazol sustituidos | |
PE20121010A1 (es) | Derivados de bencimidazol | |
PE20091842A1 (es) | Pirrolidinonas como activadores de glucoquinasa | |
PE20060374A1 (es) | Inhibidores de cinasa heterociclicos fusionados | |
PE20071322A1 (es) | Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa | |
PE20140192A1 (es) | Derivados de bencimidazol como inhibidores de cinasa pi3 | |
PE20060383A1 (es) | Nuevos derivados amino de urea ciclicos como inhibidores de quinasa | |
PE20170664A1 (es) | Agonistas del receptor de apelina(apj) y usos de los mismos | |
PE20080345A1 (es) | Derivados de piperazina como agonistas del receptor de gpr38 | |
AR055563A1 (es) | Compuestos de piridil acido acetico, agente farmaceutico y utilizacion del compuesto para preparar dicho agente | |
PE20091173A1 (es) | Derivados de heteroarilo como antagonistas de receptor de orexina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |